Одобрена рекомбинантная мультивалентная белковая вакцина против COVID-19 от вариантов XBB USA – Pусский USA – English USA – English Brazil – Português USA – Deutsch Latin America – español
Der rekombinante multivalente COVID-19-Protein-Impfstoff gegen XBB-Varianten von WestVac Biopharma/West China Medical Center, Sichuan University wurde für klinische Versuche zugelassen.
la vacuna proteica contra la COVID-19 multivalente recombinante contra las variantes XBB de WestVac Biopharma/Centro Médico de China Occidental, Sichuan University, se aprobó para ensayos clínicos por la NMPA.
Primeira vacina recombinante multivalente de proteína COVID-19 no mundo contra variantes XBB pela Biopharma/West China Medical Center (Universidade de Sichuan) aprovada para estudos clínicos pela Administração Nacional de Produtos Médicos da China. USA – English USA – English Israel – English India – English Brazil – Português
Food For Health, Wisconsin’s First Medically Tailored Meal Provider Hosts Launch Event
America’s Best Wings: Everything You Need to Know
Municipalities in restricted areas
The departmental laboratory watches over our food, our water and our animals
Salies-du-Salat. 126 walkers in favor of the heart in the countryside
The Houga. First passage of the Dental Bus
cattle. Young doctors discover the territory
DENVER, May 15, 2023 /PRNewswire/ — Onus iV Hydration, a first to market iV company, built for active living a mile above sea level, is excited...
